ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been awarded an Innovate UK grant as part of the “business-led innovation in response to global disruption” scheme, which was set up in light of the COVID-19 pandemic. The £50,000 award will be utilised to develop novel sputum-based cytokine multiplex assays. Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said: “A number of cytokines have …
Type and hit ENTER
Belfast based respiratory diagnostics company, ProAxsis is investing over £200,000 in R&D to enhance its novel ProteaseTag® technology. The company is using Invest Northern Ireland’s support for R&D to …
July 27, 2020
ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, today announces that it will be conducting a collaborative 12-month project with the Northern Ireland Connected Health Innovation Centre (CHIC), based at Ulster …
July 9, 2020
ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, has formed a new partnership with Ulster University, the largest university in Northern Ireland. The company will be collaborating on an initial 12-week …
June 29, 2020
ProAxsis Limited, the Belfast-based diagnostics company, is pleased to welcome back Elisha Cain, who re-joins the company in the newly created position of Quality Management Officer. Elisha previously completed …
June 23, 2020
ProAxsis is delighted to have been shortlisted for a Business Eye First Trust Award for the second year running. Having been declared as the “Innovative Business of the Year” …
November 18, 2019
ProAxsis was delighted to support the recent School of Pharmacy Undergraduate Awards at Queen’s University, Belfast. For the second year running, the company sponsored the award for Distinction in Industrial …
October 25, 2019
ProAxsis is pleased to confirm that Professor Stephen Smith has become the Chairman of the company’s Board of Directors with immediate effect. Stephen has held senior leadership roles in …
October 25, 2019
Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the British Lung Foundation (BLF) and the European Respiratory Society (ERS), has been …
June 3, 2019
The potential benefits of ProAxsis’ novel ProteaseTag® Active Proteinase 3 Immunoassay will be discussed at the Winter meeting of the British Thoracic Society, which takes place between December 5th-7th at …
November 26, 2018
ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces that two of its products, the ProteaseTag® Active …
September 20, 2018
ProAxsis will today be presenting new data on its highly novel active neutrophil elastase (NE) point-of-care test, NEATstik®, at the European Respiratory Society Conference, which is taking place this …
September 18, 2018
ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces that it has successfully registered a CE Mark …
August 2, 2018
ProAxsis will be presenting three abstracts at the COPD 11 Conference, which takes place between June 20th-21st 2018 in Birmingham, UK. These include: • The Development of a Novel …
June 18, 2018
ProAxsis Limited has been declared as the “Innovative Business of the Year” at the Business Eye First Trust Awards (BEFTAs) for small businesses in Northern Ireland. The glittering awards …
June 4, 2018
ProAxsis Limited has received an Invest NI Grant for Research and Development, supporting the company to develop new products using its innovative ProteaseTag® technology. The grant is part financed under …
June 1, 2018
ProAxsis confirms that new data on its ProteaseTag® technology will be presented at the American Thoracic Society Conference, which takes place between May 19th-24th in San Diego. The University …
May 2, 2018
ProAxsis is proud to be collaborating with Dr. Gunnar Schroeder and Prof. Cliff Taggart from the School of Medicine, Dentistry and Biomedical Science at Queen’s University Belfast, as part …
March 6, 2018
Following on from the commercialisation update provided in November, ProAxsis is pleased to report the first sale of NEATstik®, the company’s novel sputum-based point-of-care test, to a research laboratory conducting …
February 15, 2018
ProAxsis Limited (www.proaxsis.com) today announces that it has successfully registered a CE Mark for its ProteaseTag® Active Plasmin Immunoassay. This novel technology will enable academic and pharmaceutical researchers to specifically …
January 8, 2018
ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thoracic Society, which takes place between December 6th-8th at the Queen Elizabeth II Conference Centre, in London. …
December 5, 2017
Having reached the first anniversary following relocation to its new purpose-built laboratory on the Catalyst Inc. site in the Titanic Quarter of Belfast, ProAxsis is pleased to provide an update …
November 21, 2017
ProAxsis will be presenting further data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference, which takes place between November 1st – 5th in Indianapolis. Dr Charlene …
October 30, 2017
ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in the United States, to validate the company’s ProteaseTag® point-of-care technology for real-time management of small …
October 27, 2017
ProAxsis today announces that the company has appointed Diagenics Limited as the distributor for its ProteaseTag® Active Neutrophil Elastase Immunoassay in Great Britain and Ireland. Founded in 1994, Diagenics supply …
ProAxsis Ltd today announces that the company has signed a partnership agreement to develop activity-based immunoassays for two key respiratory proteases, utilising its ProteaseTag® technology. The partner is a …
ProAxsis will be presenting further data on its ProteaseTag® technology, at the European Respiratory Society Conference, which takes place between September 9th-13thin Milan, Italy. The company has had four abstracts …
ProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care test for measuring active neutrophil elastase, and has successfully registered the product …
Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited (www.proaxsis.com) has now gained further support for its ProteaseTag® technology, via a project co-funded by the UK’s innovation agency, …
ProAxsis was delighted to see its ProteaseTag® technology incorporated in to an important study presented at the European Cystic Fibrosis Society Conference, which took place between June 7th-10th in Seville. …
Dr David Ribeiro, CEO of ProAxsis, will be attending the Anglonordic Life Sciences Conference, taking place in London this week, and will be presenting a company update as part of …
ProAxsis Ltd is delighted to observe that its ProteaseTag® Active Neutrophil Elastase Immunoassay is prominently featured in the most recent edition of the American Journal for Respiratory and Critical Care …
ProAxsis Limited (www.proaxsis.com) is delighted to announce that it has secured a second licensing agreement with the Queen’s University of Belfast for exclusive intellectual property rights for its ProteaseTag® technology. …
ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes place between May 19th-24th in Washington DC. The company has had three …
Dr David Ribeiro, CEO of ProAxsis, will be attending the Bio-Europe Spring meeting, taking place in Barcelona on March 20th-22nd 2017, and will be presenting a company update at 11.15h on …
March 6, 2017
ProAxsis Limited (www.proaxsis.com) is further expanding its ProteaseTag® technology platform, via a project co-funded by the UK’s innovation agency, Innovate UK. ProAxsis has already registered a CE Mark in Europe …
January 25, 2017
In a significant new study, a team at the University of Dundee has shown for the first time that sputum neutrophil elastase (NE) activity, when measured using the ProteaseTag® Active NE Immunoassay, …
December 23, 2016
ProAxsis (www.proaxsis.com) was delighted to observe that measuring active neutrophil elastase (NE) by its ProteaseTag® Active NE Immunoassay was identified as a potential biomarker of bacterial exacerbation in COPD patients …
December 8, 2016
ProAxsis will this week be presenting new data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference in Orlando, Florida. The first abstract is entitled “Development of a ProteaseTag® lateral …
October 26, 2016
ProAxsis were this week delighted to host His Royal Highness, the Duke of York, at their new laboratory facilities within the Concourse III building at Catalyst Inc. Prince Andrew, who …
October 19, 2016
ProAxsis Limited (www.proaxsis.com) is pleased to announce that it has successfully registered a CE Mark for its novel ProteaseTag® Active Neutrophil Elastase Immunoassay. Neutrophil elastase is a well-recognised biomarker of …
September 30, 2016
Dr David Ribeiro, CEO of ProAxsis, will be attending the 16th Biotech in Europe Forum, taking place in Basel on September 27th-28th 2016, and will be presenting a company update at …
September 23, 2016
ProAxsis (www.proaxsis.com) is delighted to have been featured in the latest edition of Business Eye, Northern Ireland’s premium business magazine. This article follows the company’s recent move to the Catalyst …
September 16, 2016
ProAxsis (www.proaxsis.com) is undertaking business development activities with Invest Northern Ireland support. Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said: “This funding will allow us to complete …
June 20, 2016
ProAxsis will be attending the BIO 2016 conference, taking place at the Moscone Convention Center in San Francisco between June 5th-9th 2016. The BIO International Convention attracts over 15,000 biotechnology and …
June 2, 2016
ProAxsis will this week be presenting further data on its ProteaseTag® Active Neutrophil Elastase (NE) Immunoassay, at the American Thoracic Society Conference in San Francisco. The abstract is entitled “Development of …
May 16, 2016
ProAxsis is delighted to announce that Dr Kelly Moffitt has joined the company in the role of Senior Project Manager, and will report in to the CEO, Dr David Ribeiro. …
May 9, 2016
ProAxsis CEO David Ribeiro was interviewed by ProActive Investors UK. Watch the video on Stock-Tube
May 4, 2016
ProAxsis is pleased to announce the appointment of Sarah Ganniclefft to the newly created role of Sales and Marketing Manager. Sarah joins the company from Becton Dickinson, where she …
April 20, 2016
Dr David Ribeiro, CEO of ProAxsis, will be attending the 10th anniversary Biotrinity conference, taking place in London on April 25th-27th 2016, and will be presenting a company update at 16.00h …
April 19, 2016
ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland
tel +44 (0)28 9073 0444
email info@proaxsis.com
LATEST TWEETS
ProAxsis
RT @ProfJDChalmers: Great to see neutrophil elastase and biomarker guided endotypes centre stage in the future of bronchiectasis management…
9 days ago - ProAxsisRT @ProfJDChalmers: We are delighted to publish the final results of the WILLOW trial of DPP1 inhibition in bronchiectasis in the @NEJM - t…
14 days ago - ProAxsisRT @ProfJDChalmers: We have known for many years that neutrophils are central to the pathophysiology of bronchiectasis, and neutrophil elas…
14 days ago - ProAxsisRT @InvestNI: Great news today for @QUB who has been granted significant funding from @UKRI_News Strength in Places Fund #innovation >> htt…
41 days ago - ProAxsisCopyright © 2016-2018 - ProAxsis - All rights reserved.
Split Blog - Featured Post | ProAxsis